Article Figures & Data
Figures
- Fig. 1.
Distribution and relative frequency of ABL kinase domain mutations found in our study.
- Fig. 2.
Position and relative frequency of mutations according to disease phase. CP, chronic phase; AP, accelerated phase; myBC, myeloid blast crisis; lyBC, lymphoid blast crisis.
- Fig. 3.
Position and relative frequency of mutations according to type of resistance.
Tables
- Table 1.
Classification of the patient population under study
All Primary resistance (%) Acquired resistance (%) Total no. 297 152 (51) 145 (49) Chronic phase 198 116 (59) 82 (41) Imatinib frontline 44 28 (64) 16 (36) Imatinib after α-IFN failure 154 107 (69) 47 (31) Accelerated phase 21 5 (24) 16 (76) myeloid blast crisis 32 5 (16) 27 (84) lymphoid blast crisis/Ph+ ALL 46 7 (15) 39 (85) - Table 2.
Frequency of mutations according to disease phase
All Mutated (%) Total no. 297 127 (43) Chronic phase 198 54 (27) Imatinib frontline 44 6 (14) Imatinib after α-IFN failure 154 48 (31) Accelerated phase 21 11 (52) Myeloid blast crisis 32 24 (75) Lymphoid blast crisis/Ph+ ALL 46 38 (83) - Table 3.
Frequency of mutations according to type of resistance
All Mutated (%) Total no. 297 127 (43) Primary resistance 152 45 (30) Hematologic 18 8 (44) Cytogenetic 134 37 (28) Acquired resistance 145 82 (57) Loss of CCR 52 12 (23) Loss of HR 33 18 (55) Progression to AP/BC 60 52 (87) Abbreviations: HR, hematologic response; CCR, complete cytogenetic response.
December 2006
Volume 12, Issue 24
Volume 12, Issue 24
Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia
Jump to section
Advertisement